About GenDx
GenDx is a company based in Utrecht (Netherlands) founded in 2005 was acquired by Eurobio scientific in August 2022. GenDx offers products and services including HLA Typing, Chimerism Monitoring, NGS KIR Typing, NGS MICA, MICB Typing, and Custom Lab Service. GenDx operates in a competitive market with competitors including Omniome, Tessera Therapeutics, HitGen, Phase Genomics and Hexagon Bio, among others.
- InvestorsEurobio scientific
& 1 more
- Acquired byEurobio scientific
(Aug 2022)
Products & Services of GenDx
GenDx offers a comprehensive portfolio of products and services, including HLA Typing, Chimerism Monitoring, NGS KIR Typing, NGS MICA, MICB Typing, and Custom Lab Service.
Provides gene typing for transplant compatibility and donor matching.
Tracks cell mixtures in patients post-transplantation for health monitoring.
Offers next-generation sequencing for killer cell immunoglobulin receptors.
Performs sequencing for major histocompatibility complex class I chain genes.
Delivers tailored diagnostic solutions for specific research needs.
Funding Insights of GenDx
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of GenDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | – | Series B | – | Ampersand Capital | – |
2 investors in total: 2 institutional.
Investors in GenDx
GenDx has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Eurobio scientific and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | – | ampersandcapital.com | Boston, United States | |
Provider of vitro diagnostic services and products | 1997 | eurobio-scientific.com | Paris, France |
Investor details for GenDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GenDx
3 dated milestones of GenDx across 17 years, from founding to its latest funding, stage changes and deals.
- Founded GenDx is founded.
- Funding First funding round.
- Exit Acquired by Eurobio scientific.
Competitors of GenDx
GenDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, Tessera Therapeutics, HitGen, Phase Genomics and Hexagon Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| omniome.com | 2013 | San Diego, United States | $160.23M | 164 | Genome sequencing platform is provided for clinical diagnostics. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| hitgen.com | 2012 | Lanzhou, China | $39.11M | – | DNA-encoded libraries are developed for drug discovery applications. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| hexagonbio.com | 2017 | Menlo Park, United States | $205.6M | 34 | Bioinformatics tools are provided for analyzing microbial genomic sequencing data. | |
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| novellusdx.com | 2011 | Jerusalem, Israel | $85.5M | – | Developer of technology for precision cancer diagnosis and therapies | |
| bgi.com | 1999 | Shenzhen, China | – | 25 | BGI is engaged in genomics and precision medicine solutions. | |
| genewiz.com | 1999 | South Plainfield, United States | – | 452 | Genomic services are provided for the life sciences industry. | |
| seqone.com | 2017 | Montpellier, France | $48.79M | – | Bioinformatics tools for genome sequencing data analysis are provided. |
Detailed competitors of GenDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GenDx
The website of GenDx (gendx.com) receives about 13.7K visits a month and ranks #2,283,053 among all websites worldwide, #3,120 in Biotechnology and Pharmaceuticals.
- Monthly visits13.7K
▲ 41.4% vs previous month
- Unique visitors4.6K
per month
- Global rank#2,283,053
among all websites
- Category rank#3,120
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit19 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with GenDx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| onelambda.com | 100% | – | – | View details | |
| hoxworth.org | 91% | 680.7K | #476,968 | View details | |
stanfordbloodcenter.org | stanfordbloodcenter.org | 70% | – | #258,003 | – |
| nmdp.org | 65% | 323.1K | #114,953 | View details | |
discoverycord.com.tw | discoverycord.com.tw | 63% | – | #8,867,929 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for GenDx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Gendx
Complete news archive for GenDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to GenDx
10 companies that operate in the same segment as GenDx (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GenDx
GenDx was founded in 2005 and raised its 1st funding round 14 years after it was founded.
GenDx is headquartered in Utrecht, Netherlands.
GenDx was founded in 2005 in Utrecht, Netherlands, within the in vitro diagnostics sector. Products focused on HLA typing for transplant applications are developed and marketed, including reagents and kits for Sanger sequencing and next-generation sequencing. Analysis software for sequencing data is also provided, alongside educational services to support clinical and research use. Operations emphasize precision in transplant compatibility assessments.
GenDx's top competitors include Tessera Therapeutics, Novogene Corporation and Phase Genomics.
GenDx offers HLA Typing, Chimerism Monitoring, NGS KIR Typing, NGS MICA, MICB Typing, and Custom Lab Service.
GenDx has 2 investors. Key investors include Eurobio scientific, and Ampersand Capital Partners.
Yes. GenDx was acquired by Eurobio scientific in August 2022.